ProHealth health Vitamin and Natural Supplement Store and Health
Log In  |  My Account  |  View Cart  View Your ProHealth Vitamin and Supplement Shopping Cart
800-366-6056  |  Contact Us  |  Help

|
|
|
|

Trending News

Missing protein explains link between obesity, diabetes

Fish oil use associated with brain volume preservation

The Brain Boosting and Fatigue Fighting B-12

Genetic basis for distinct type of autism uncovered

Unsuspected aspect of immune regulation revealed: Role of B cells

IBS, Crohn’s Disease, Colitis, and Other Digestive Disorders

Explaining 'Healthy' Obesity

Sinus Congestion and Sinusitis, Healing Naturally

In the gut, immunity is a two-way street

Omega 3 Fatty Acids Lessen Severity of Osteoarthritis in Mice

 
Print Page
Email Article

Omega-3 ratio for positive depression effect is 60% or more EPA

  [ 15 votes ]   [ Discuss This Article ]
www.ProHealth.com • November 25, 2011


Article:
Meta-analysis of the effects of eicosapentaenoic acid (EPA) in clinical trials in depression – Source: Journal of Clinical Psychiatry, Sep 6, 2011

By M Elizabeth Sublette, MD, PhD, et al.

[Note: The full text pdf of this article can be found at http://www.tritolonen.fi/files/pdf/Sublette_2011.pdf. It includes a discussion of various hypotheses regarding why these EPA-DHA ratios and relative daily amounts provide therapeutic benefit for primary depression. DHA & EPA are found mainly in fish oil. ]

Abstract:
Objective: Randomized trials of omega-3 polyunsaturated fatty acid (PUFA) treatment for depression have differed in outcome. Recent meta-analyses ascribe discrepancies to differential effects of eicosapentaenoic acid (EPA) versus docosahexaenoic acid (DHA) and to diagnostic heterogeneity.

This meta-analysis tests the hypothesis that EPA is the effective component in PUFA treatment of major depressive episodes.

Data Sources: PubMed/MeSH was searched for studies published in English from 1960 through June 2010 using the terms fish oils (MeSH) AND (depressive disorder [MeSH] OR bipolar depression) AND randomized controlled trial (publication type). The search was supplemented by manual bibliography review and examination of relevant review articles.

Study Selection: The search yielded 15 trials involving 916 participants. Studies were included if they had a prospective, randomized, double-blinded, placebo-controlled study design; if depressive episode was the primary complaint (with or without comorbid medical conditions); if omega-3 PUFA supplements were administered; and if appropriate outcome measures were used to assess depressed mood.

Data Extraction: Extracted data included study design, sample sizes, doses and percentages of EPA and DHA, mean ages, baseline and endpoint depression ratings and standard deviations for PUFA and placebo groups, and P values.

The clinical outcome of interest was the standardized mean difference in the change from baseline to endpoint scores on a depression rating scale in subjects taking PUFA supplements versus subjects taking placebo.

Data Synthesis: In a mixed-effect model, percentage of EPA in the supplements was the fixed-effect predictor, dichotomized into 2 groups: EPA less than 60% or EPA 60% or more of the total EPA + DHA. Secondary analyses explored the relevance of treatment duration, age, and EPA dose.

Results:

• Supplements with 60% or more EPA [of total EPA + DHA] showed benefit on standardized mean depression scores (effect size = 0.532; 95% CI, 0.277–0.733; t = 4.195; P < .001) versus supplements with less than 60% EPA (effect size = -0.026; 95% CI, -0.200 to 0.148; t = -0.316; P = .756), with negligible contribution of random effects or heteroscedasticity and with no effects of treatment duration or age.

• Supplements with less than 60% EPA were ineffective.

Exploratory analyses supported a nonlinear model, with improvement determined by the dose of EPA in excess of DHA, within the range of 200 to 2,200 mg/d of EPA.

Conclusions:

• Supplements containing 60% or more EPA of total EPA + DHA, in a dose range of 200 to 2,200 mg/d of EPA in excess of DHA, were effective against primary depression.

• Translational studies are needed to determine the mechanisms of EPA’s therapeutic benefit.

Source: Journal of Clinical Psychiatry, Sep 6, 2011. PMID:21939614, by Sublette ME, Ellis SP, Geant AL, Mann JJ. New York State Psychiatric Institute, New York, NY, USA. [Email: es2316@columbia.edu]





Discuss This Article Post a Comment 




[ Be the first to comment on this article ]




 
Free Chronic Fatigue Syndrome and Fibromyalgia Newsletters
Subscribe to
Our FREE
Newsletter
Subscribe Now!
Receive up-to-date ME/CFS & Fibromyalgia treatment and research news
 Privacy Guaranteed  |  View Archives

Featured Products

Ultra EPA  - Fish Oil Ultra EPA - Fish Oil
Ultra concentrated source of essential fish oils
Energy NADH™ 12.5mg Energy NADH™ 12.5mg
Improve Energy & Cognitive Function
Ultra ATP+, Double Strength Ultra ATP+, Double Strength
Get energized with malic acid & magnesium
Vitamin D3 Extreme™ by ProHealth Vitamin D3 Extreme™ by ProHealth
50,000 IU Vitamin D3 - Prescription Strength
FibroSleep™ by ProHealth FibroSleep™ by ProHealth
The All-in-One Natural Sleep Aid

Natural Remedies

Running on Empty? Fuel Up with NADH Running on Empty? Fuel Up with NADH
Itching to Find Dry Skin Relief? Itching to Find Dry Skin Relief?
The Big Blue Fish that Helps Chase the Blues Away The Big Blue Fish that Helps Chase the Blues Away
Repair Damaged Mitochondria and Reduce Fatigue Up to 45% Repair Damaged Mitochondria and Reduce Fatigue Up to 45%
2 test library cats 2 test library cats

FIBROMYALGIA RESOURCES
What is Fibromyalgia?
Fibromyalgia 101
Fibromyalgia Symptoms
Fibromyalgia Treatments
| CFS RESOURCES
What is CFS?
ME/CFS 101
ME/CFS Symptoms
ME/CFS Treatments
| FORUMS
Fibromyalgia
ME/CFS
ADVANCED MEDICAL LABS
WHOLESALE  |  AFFILIATES
GUARANTEE
CONTACT US
PRIVACY
RSS
SITE MAP
ProHealth on Facebook  ProHealth on Twitter  ProHealth on Pinterest  ProHealth on Google Plus
Credit Card Processing